# 162 mg of Aspirin for Prevention of Preeclampsia

> **NCT05221164** · PHASE4 · UNKNOWN · sponsor: **Methodist Medical Center of Illinois** · enrollment: 200 (estimated)

## Conditions studied

- Preeclampsia

## Interventions

- **DRUG:** Aspirin 162 mg

## Key facts

- **NCT ID:** NCT05221164
- **Lead sponsor:** Methodist Medical Center of Illinois
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-06
- **Primary completion:** 2022-06-09
- **Final completion:** 2022-06-09
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2022-02-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05221164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05221164, "162 mg of Aspirin for Prevention of Preeclampsia". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05221164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*